CJC-1295 WITH DAC 5mg

CJC-1295 WITH DAC 5mg
£35.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

CJC-1295 with DAC (Drug Affinity Complex) 5mg

is a long-acting synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analogue, designed to provide a sustained, steady increase in the body's natural growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. 

 

Mechanism and Half-Life

The primary difference in the "with DAC" version is a molecular modification that prolongs its action in the body. 

  • Albumin Binding: The DAC complex is a lysine derivative that binds to albumin, a common protein in the bloodstream.
  • Extended Half-Life: This binding protects the peptide from rapid breakdown by enzymes, increasing its half-life to approximately 6 to 8 days, compared to the 30 minutes of the "no DAC" version.
  • Sustained Release: A single injection can elevate GH levels for 6 days or more, and IGF-1 levels for up to 9-11 days, allowing for less frequent dosing.
  • Preserved Pulsatility: Studies have shown that while it increases the baseline (trough) GH levels, it still preserves the body's natural pulsatile rhythm of GH secretion. 

 

Potential Benefits (Research & Anecdotal)

Users and researchers suggest several benefits, primarily derived from the increase in GH and IGF-1 levels: 

  • Improved Body Composition: Enhanced fat loss and increased lean muscle mass through increased protein synthesis and fat metabolism.
  • Enhanced Recovery: Faster repair of tissues, tendons, ligaments, and joints after injury or intense exercise.
  • Anti-Aging Effects: Improved skin elasticity, better sleep quality, and increased energy levels are commonly reported due to increased collagen synthesis and support for cellular health.
  • Convenience: The long half-life makes it suitable for individuals preferring infrequent dosing schedules (typically once or twice weekly). 

 

Safety and Regulatory Status

The use of CJC-1295 with DAC is not without risks and lacks full regulatory approval. 

  • FDA Status: The peptide is not FDA-approved for human use. It reached Phase II clinical trials for growth hormone deficiency but development was discontinued after a subject's death, though it was considered unrelated to the treatment. In late 2023 and 2024, the FDA proposed that CJC-1295 DAC not be included on the list of approved bulk drug substances for compounding, citing safety concerns including potential immunogenicity and an increased heart rate.
  • WADA Status: It is a prohibited substance under the World Anti-Doping Agency (WADA) Prohibited List.
  • Side Effects: Common side effects include injection site reactions, facial flushing, headaches, and water retention. Continuous GH elevation may also theoretically lead to receptor desensitization or increased insulin resistance over long-term use. 

Warning: CJC-1295 with DAC is sold as a "research chemical" and is not intended for human consumption without medical supervision. Always consult a qualified healthcare provider before considering peptide therapy.